JPRN-jRCT2080221286未知1 期
A Phase I study of TSU-68 in combination with Carboplatin and Paclitaxel in patients with Advanced Non-Small Cell Lung Cancer
试验速览
- 阶段
- 1 期
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •1)Patients must be 20 years or more and 74 years or less with Performance Status of 0 to 1.
- •2)Life expectancy is 12 weeks or more.
- •3)Adequate oral intake.
- •4)Patients must have histologically confirmed stage IIIb/IV or recurrent NSCLC.
排除标准
- •1)Patients have colon disorder that is active inflammation.
- •2)Concurrent of other malignancy.
- •3)Patients who have been previously treated with investigational products within the past 4 weeks.
- •4)The subject has hypersensitivity reaction related to CBDCA, PTX or premedication.
研究者
相似试验
未知
2 期
An early phase II study of TSU-68 in combination with docetaxel in patients with advanced and metastatic breast cancer progressing anthracycline containing regimen.Breast cancerJPRN-jRCT2080221143Taiho Pharmaceutical Co., Ltd.19
未知
1 期
A Phase I study of TSU-68 in combination with S-1 in patients with advanced hepatocellular carcinoma who are not candidates for conventional therapyHepatocellular carcinomaJPRN-jRCT2080221925Taiho Pharmaceutical Co., Ltd.18
未知
2 期
A randomized phase II trial of TSU-68 in patients with advanced gastric cancerGastric cancerJPRN-jRCT2080221290Taiho Pharmaceutical Co., Ltd.92
未知
2 期
A Phase II study of TSU-68 in patient with hepatocellular carcinomaHepatocellular CarcinomaJPRN-jRCT2080221054Taiho Pharmaceutical Co., Ltd.100
进行中（未招募）
不适用
A Study of TRU-016 in Combination with Rituximab and Bendamustine in Subjects with Relapsed Slow-Growing Cancer of the Lymph Nodes (Indolent Lymphoma)Relapsed Indolent LymphomaMedDRA version: 14.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2010-023335-41-ATAbbott88